Immutep Ltd ADR is a Sydney-based biotechnology company focused on pioneering immunotherapy solutions for cancer and autoimmune disorders. The firm is advancing its lead product candidates designed to enhance immune responses against tumors, positioning itself as a frontrunner in the oncology space. Supported by a robust pipeline and strategic collaborations, Immutep is well-placed to leverage growth opportunities and contribute significantly to the evolving landscape of immunotherapy as it progresses through critical clinical trial phases. Show more

Location: AUSTRALIA SQUARE, SYDNEY, NSW, AUSTRALIA, 2000, L 12 95 Pitt St, Sydney, NSW, 2000, USA | Website: https://www.immutep.com | Industry: BIOTECHNOLOGY | Sector: HEALTHCARE

Market Cap

385.6M

52 Wk Range

$1.32 - $3.32

Previous Close

$2.62

Open

$2.65

Volume

156,478

Day Range

$2.56 - $2.68

Enterprise Value

308M

Cash

67.41M

Avg Qtr Burn

-15.51M

Insider Ownership

0.01%

Institutional Own.

2.22%

Qtr Updated

06/30/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Eftilagimod alfa (efti) + Keytruda Details Non-small cell lung carcinoma (1L NSCLC)	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Eftilagimod Alpha (LAG-3lg or IMP321) (APC activating Soluble LAG-3 Protein) Details Metastatic breast cancer	Phase 2/3 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Eftilagimod Alpha (LAG-3lg or IMP321) + Keytruda Details Head and neck squamous cell carcinoma (1L HNSCC)	Phase 2b Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Neoadjuvant Eftilagimod Alfa (Efti) +/- SoC Details Early-stage HR+/HER2-negative breast cancer	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Eftilagimod Alpha + Pembrolizumab Details Soft tissue sarcoma	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Eftilagimod Alpha (LAG-3lg or IMP321) (APC activating Soluble LAG-3 Protein) and avelumab Details Non-small cell lung carcinoma (1L NSCLC)	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
IMP761 (LAG-3 agonist) Details Autoimmune disease	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Eftilagimod Alpha (LAG-3lg or IMP321) (APC activating Soluble LAG-3 Protein) and avelumab Details Solid tumor/s, Cancer, Urothelial cancer	Phase 1 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
IMP761 (Agonist AB) Details COVID-19	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.